NCT05893797View on ClinicalTrials.gov

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

September 16, 2024

Study Completion Date

September 16, 2024

Conditions
Type 1 DiabetesType 2 DiabetesType 2 Diabetes Treated With Insulin
Interventions
DRUG

Insulin Lispro

As prescribed.

DEVICE

Tempo Smart Button

Attached to the Tempo Pen

DEVICE

Dexcom G6 CGM

Continuous glucose monitor

DEVICE

Glooko Research Medical App (RMA)

Installed on a study provided android phone.

Trial Locations (9)

6202

Centre Hospitalier Universitaire de Nice - Hôpital l'Archet, Nice

13005

CHU - l'Assistance Publique - Hôpitaux de Marseille, Marseille

14033

CHU de Caen Hôpital Cote de Nacre, Caen

25030

CHU de Besancon Hopital Jean Minjoz, Besançon

38043

Chu de Grenoble, Grenoble Cédex 9

67098

CHU Strasbourg-Hautepierre, Strasbourg

69008

CHU de Lyon, Lyon

69200

Groupe Hospitalier Mutualiste Les Portes du Sud, Vénissieux

91100

Centre Hospitalier Sud Francilien-Pharmacie, Corbeil-Essonnes

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05893797 - A Study of LY8888AX in Participants Using a Connected Insulin Management Platform | Biotech Hunter | Biotech Hunter